|
EQS-News: Eckert & Ziegler SE
/ Key word(s): Product Launch
Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF). The test production demonstrated that the choice of technology was appropriate to achieve the expected parameters of the product. In parallel with production, Eckert & Ziegler has commenced the validation process to produce GMP-grade Ac-225, crucial for clinical and commercial use. It is expected to become available in the first half of 2025, unlocking new opportunities for pharmaceutical companies developing alpha-emitting radiopharmaceuticals. The production facility employs innovative cyclotron-based methods to generate Ac-225 from Radium-226, marking a pivotal advancement in isotope production. “This milestone underscores our commitment to advancing cancer treatment through the reliable supply of radioisotopes,” said Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. “The commencement of Ac-225 production not only addresses the current shortage but also fortifies Eckert & Ziegler’s position as a key player in the future of radioligand therapy.” The successful start of Ac-225 production is a direct result of the close collaboration between Eckert & Ziegler and the ÚJF. Drawing on decades of expertise in nuclear research and radiopharmaceutical development, ÚJF has played a crucial role in designing and optimizing this production pathway for Ac-225. Incorporating custom-engineered solutions by Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division, the production process is designed to be efficient and sustainable. The start of production positions Eckert & Ziegler at the forefront of the radiopharmaceutical industry's transformation, offering a reliable and scalable source of Ac-225 for clinical development and commercial manufacturing. About Eckert & Ziegler SE Contact
02.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Eckert & Ziegler SE |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2041567 |
| End of News | EQS News Service |
|
|
2041567 02.12.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
